Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis. - Wikidata - wikimedia - TriplyDB

Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis.

Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis.

http://www.wikidata.org/entity/Q34581804

about

The role of regulatory T cells in the pathogenesis of sepsis and its clinical implication Neutrophil mobilization from the bone marrow during polymicrobial sepsis is dependent on CXCL12 signaling.Type I interferon signaling in hematopoietic cells is required for survival in mouse polymicrobial sepsis by regulating CXCL10.Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth.Persistent neutrophil dysfunction and suppression of acute lung injury in mice following cecal ligation and puncture sepsis.Impact of sepsis on CD4 T cell immunity Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony.A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma B cells enhance early innate immune responses during bacterial sepsis.The role of regulatory T cells in immune dysfunction during sepsis.CCR4 Controls the Suppressive Effects of Regulatory T Cells on Early and Late Events during Severe Sepsis.Thermal injury-plus-sepsis contributes to a substantial deletion of intestinal mesenteric lymph node CD4 T cell via apoptosis Annexin A2 Modulates ROS and Impacts Inflammatory Response via IL-17 Signaling in Polymicrobial Sepsis Mice.TNF and regulatory T cells are critical for sepsis-induced suppression of T cells Sepsis-induced immune dysfunction: can immune therapies reduce mortality?Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists.Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care Blood stream infection is associated with altered heptavalent pneumococcal conjugate vaccine immune responses in very low birth weight infants.Adoptive transfer of fibrocytes enhances splenic T-cell numbers and survival in septic peritonitis.Sepsis induces early alterations in innate immunity that impact mortality to secondary infection.Potential of immunomodulatory agents for prevention and treatment of neonatal sepsis.Interleukin-37 Enhances the Suppressive Activity of Naturally Occurring CD4+CD25+ Regulatory T Cells.Endogenous IL-10 regulates sepsis-induced thymic apoptosis and improves survival in septic IL-10 null mice.The immune system's role in sepsis progression, resolution, and long-term outcome.Human Myeloid-derived Suppressor Cells are Associated With Chronic Immune Suppression After Severe Sepsis/Septic Shock.Thymic Stromal Lymphopoietin Improves Survival and Reduces Inflammation in Sepsis.Adoptive transfer of CD34(+) cells during murine sepsis rebalances macrophage lipopolysaccharide responses.Immune cells and oxidative stress in the endotoxin tolerance mouse model.Potential Immunotherapeutics for Immunosuppression in Sepsis.Sepsis leads to a reduced antigen-specific primary antibody response.T regulatory cells participate in the control of germinal centre reactions.Small-molecule inhibitor sorafenib regulates immunoreactions by inducing survival and differentiation of bone marrow cells.

P2860

Q27004368-6A8D310C-1A77-4759-BBF0-E5C5B016D9AE Q30419805-61D9B6E3-5090-4FC5-BB6D-2FF9376ED455 Q33656087-A177DA1A-8940-4B97-8200-22C8241AEB61 Q33828888-5D15F156-2907-498A-93BA-C80744EAD778 Q33896697-5E9DE513-E2A7-43F3-9F31-750290717892 Q34076226-8609E916-9B52-453D-B14D-6CB84D4FE523 Q34341378-6CB94A98-1EF3-40ED-BCDE-0EBE8344A17E Q34585151-86F9CDBF-1021-4ADE-B3F0-1D609E538ABA Q34699543-BF323C04-2D63-4622-A385-74E35ECA7430 Q35144572-8536F2E7-58DE-4E6D-BE94-BF91AE5791ED Q35205781-83DC8EC6-1AEC-4D7C-BABE-F184714827E7 Q35703434-8ADD27B6-5B3B-4C20-B5D4-D6563225A348 Q36007864-EF9620AC-4CDA-43DF-8773-839C294A6CA6 Q36070617-101FE5C0-9733-46F5-9D1A-161F8E338479 Q36410571-0F03EF69-B572-4DB2-92A5-9FCC86F78F52 Q36430684-3D22DFAA-BC5C-4975-B1D6-9FED1B47D1AB Q36843705-5FEF5A76-EF37-4735-8E55-383C945C4154 Q36995660-93F82C93-8C9D-46A8-82F5-C1DEF107F3E8 Q37042911-52C80E8A-C5A1-4BAD-920D-7D7AA75B67A8 Q37069103-519A3BEA-0BB7-466C-9DC2-F64F205002D4 Q37166367-FFD49620-70AB-4A05-BD4A-BBBB3219B1A1 Q37260284-529ED02A-6296-4BDE-AF5D-F22215F9422F Q37492932-061923D6-7BC3-48BB-9075-AC3640C1A3BE Q37618990-BA4B3195-3791-4E02-AC5B-D4329E71EBDA Q38991057-2182DE9A-CCE8-4B2B-8C15-EECDB0A6DA83 Q39779016-E73E860E-28CF-4007-9A98-3EEB50D604E7 Q40770616-39FACD14-65B1-4CFA-9C9E-F560A207AF5F Q44880503-A2CC2256-A2DA-4C10-90FA-D505D8EF32F1 Q46431958-51997A97-9017-4820-9832-5E532C4E8D95 Q47102338-8A05A74B-2AED-4604-B468-5D6D974803D5 Q50981888-ADA1CE1C-AD41-4599-BF29-D00AC33CD8A5 Q51006330-1CC84BFE-1D9E-4DC5-B552-CB6AF73B97EC Q51627647-D5AED83C-AB9C-4F17-8EAA-06AAC91C08A2

P2860

Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis.

http://www.wikidata.org/entity/Q34581804

description

2007 nî lūn-bûn

@nan

2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

name

Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis.

@ast

Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis.

@en

Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis.

@nl

type

label

Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis.

@ast

Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis.

@en

Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis.

@nl

prefLabel

Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis.

@ast

Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis.

@en

Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis.

@nl

P1433

Q34581804-2EBC0225-C4B9-4BA9-A85A-404B3BF9920E

P1476

Q34581804-0EB6D9B1-B004-4815-B699-9AB0B880BB53

P2093

Q34581804-04AA7755-38E7-4A19-A7E6-D5083451D57E

Q34581804-0D440302-C05F-46E5-BB07-46ABCDBFAC2A

Q34581804-16D94E8D-65AA-4DE6-A175-401DA07D590E

Q34581804-24A01F2C-53C3-4A01-BCDA-0A671CF565EA

Q34581804-35603549-EBC3-4609-BB6E-878BFE17CE82

Q34581804-367F54B3-AE11-4DA9-B293-0C54CF911FF3

Q34581804-3CE99791-3838-45A4-8013-29F49F63ACD1

Q34581804-8E4A4D9B-8A03-4A1E-BE84-F706400FFB6F

Q34581804-B9D5BF51-70DF-4366-9835-1FEC561DB035

Q34581804-CE0E334F-AADD-4E0F-A708-6C1B646E3D66

P2860

Q34581804-0E4DAA32-5A20-421F-BF6E-3978A716D12D

Q34581804-358C3871-A66C-44E8-BD40-370E88530537

Q34581804-3779B323-5BB6-4B09-8144-8123E9F388D6

Q34581804-43709A7B-4FCA-4662-A3E1-FC95AD734D47

Q34581804-4E8D8357-94E0-479E-B0B6-7500A5939D95

Q34581804-50F84766-C5E3-4B9F-83A8-6C7C47D29CEA

Q34581804-53479DCB-DCF4-459B-A806-2DCD214EC271

Q34581804-5D8B2EBC-7733-4F09-9647-D14E18E735A4

Q34581804-5E65DB8F-D338-44B9-BFF0-4340ED9D644F

Q34581804-680DEF30-1A0F-4904-8221-8E471C00D8A3

P304

Q34581804-58EE7EC1-D4D6-4F86-B448-BF0DA8B65656

P31

Q34581804-B96EF628-E295-4CF0-BE73-C5F41CEF6FCE

P356

Q34581804-57F4025E-DB81-4074-B371-4F9584EB4A2A

P407

Q34581804-9F6F9FF3-7524-4552-9A8E-268DF50C7EA2

P433

Q34581804-9DE546A4-508D-4FAF-A391-6C2EA8A366B6

P478

Q34581804-849D25B0-21DB-4594-B778-CEA867BE436D

P50

Q34581804-763A7969-A6DE-410B-A4D7-A6920EEEE3B0

P577

Q34581804-3257E088-85D8-4A88-AF46-18A2E0299642

P5875

Q34581804-D0E2DACE-6851-4398-AEA1-CF8F3A1EB47B

P698

Q34581804-9F83AB27-E666-4112-9A95-143F5B6C7AB8

P921

Q34581804-48E45916-7FE4-4818-9920-BB320563AAE8

Q34581804-5E7C34E8-5B33-4A9A-9A87-2F29D4221A7B

P932

Q34581804-496CD7AA-0E47-420C-93AE-541F12B8062A

P356

BLOOD-2007-04-087171

P1433

P1476

Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis.

@en

P2093

Changqing Xia

http://www.w3.org/2001/XMLSchema#string

Chun Shiang Chung

http://www.w3.org/2001/XMLSchema#string

James L Wynn

http://www.w3.org/2001/XMLSchema#string

Jason S Weinstein

http://www.w3.org/2001/XMLSchema#string

Kindra M Kelly-Scumpia

http://www.w3.org/2001/XMLSchema#string

Lyle L Moldawer

http://www.w3.org/2001/XMLSchema#string

Mark A Atkinson

http://www.w3.org/2001/XMLSchema#string

Matthew J Delano

http://www.w3.org/2001/XMLSchema#string

Michael J Clare-Salzler

http://www.w3.org/2001/XMLSchema#string

Philip O Scumpia

http://www.w3.org/2001/XMLSchema#string

P2860

Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis

The epidemiology of sepsis in the United States from 1979 through 2000

The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation.

Immune system dysfunction and autoimmune disease in mice lacking Emk (Par-1) protein kinase.

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance.

GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations.

Adoptive transfer of in vitro-stimulated CD4+CD25+ regulatory T cells increases bacterial clearance and improves survival in polymicrobial sepsis.

Increased natural CD4+CD25+ regulatory T cells and their suppressor activity do not contribute to mortality in murine polymicrobial sepsis.

The contribution of CD4+ CD25+ T-regulatory-cells to immune suppression in sepsis

In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice.

P304

3673-3681

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-04-087171

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6149908

http://www.w3.org/2001/XMLSchema#string

P698

17690255

http://www.w3.org/2001/XMLSchema#string

P921

P932

2077315

http://www.w3.org/2001/XMLSchema#string